Cancer Chemotherapy and Pharmacology

, Volume 63, Issue 1, pp 65–74 | Cite as

A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies

  • Laura Q. M. Chow
  • Daniel L. Gustafson
  • Cindy L. O’Bryant
  • Lia Gore
  • Michele Basche
  • Scott N. Holden
  • Mark C. Morrow
  • Stacy Grolnic
  • Brian R. Creese
  • Kaye L. Roberts
  • Kat Davis
  • Russell Addison
  • S. Gail Eckhardt
Original Article



This study evaluated the safety, toxicity, pharmacological properties and biological activity of PI-88, a heparanase endoglycosidase enzyme inhibitor, with fixed weekly docetaxel in patients with advanced solid malignancies.

Experimental design

This was a phase I study to determine the maximal-tolerated dose of escalating doses of PI-88 administered subcutaneously for 4 days per week, along with docetaxel 30 mg/m2 given on days 1, 8, 15 of a 28-day schedule.


Sixteen patients received a total of 42 courses of therapy. No dose-limiting toxicities were observed despite escalation to the highest planned dose level of PI-88 (250 mg/day). Frequent minor toxicities included fatigue (38%), dysgeusia (28.5%), thrombocytopenia (12%), diarrhea (14%), nausea (12%), and emesis (10%) in the 42 courses. No significant bleeding complications were observed. One patient developed a positive anti-heparin antibody test/serotonin releasing assay with positive anti-platelet factor 4/PI-88 antibodies and grade 1 thrombocytopenia in cycle 5, and was withdrawn from the study without any sequelae. PI-88 plasma concentrations (mirrored by APTT) and urinary elimination were linear and dose-proportional. Docetaxel did not alter the pharmacokinetic (PK) profile of PI-88, nor did PI-88 affect docetaxel PK. No significant relationship was determined between plasma or urine FGF-2, or plasma VEGF levels and PI-88 dose/response. Although no objective responses were observed; 9 of the 15 evaluable patients had stable disease for greater than two cycles of therapy.


PI-88 administered at 250 mg/day for 4 days each week for 3 weeks with docetaxel 30 mg/m2 on days 1, 8 and 15, every 28 days, was determined to be the recommended dose level for phase II evaluation. This combination was well tolerated without severe toxicities or PK interactions.


PI-88 Docetaxel Heparanase inhibitor Angiogenesis Clinical trial Advanced malignancies 


  1. 1.
    Amiral J, Bridey F, Dreyfus M, Vissoc AM, Fressinaud E, Wolf M, Meyer D (1992) Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 68:95–96PubMedGoogle Scholar
  2. 2.
    Anderson RL, Lelekakis M, Lowen D et al (1998) Inhibition of lung metastasis from a breast carcinoma using PI88, a heparanase inhibitor. (abstr). Proc Metastatic Res SocGoogle Scholar
  3. 3.
    Baker SD, Zhao M, Lee CK, Verweij J, Zabelina Y, Brahmer JR, Wolff AC, Sparreboom A, Carducci MA (2004) Comparative pharmacokinetics of weekly and every-three-weeks docetaxel. Clin Cancer Res 10:1976–1983PubMedCrossRefGoogle Scholar
  4. 4.
    Bareschino MA, Morgillo F, Ciardiello F (2007) Combination of standard chemotherapy and targeted agents. J Thorac Oncol 2:S19–S23PubMedCrossRefGoogle Scholar
  5. 5.
    Basche M, Gustafson DL, Holden SN, O’Bryant CL, Gore L, Witta S, Schultz MK, Morrow M, Levin A, Creese BR, Kangas M, Roberts K, Nguyen T, Davis K, Addison RS, Moore JC, Eckhardt SG (2006) A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors. Clin Cancer Res 12:5471–5480PubMedCrossRefGoogle Scholar
  6. 6.
    Belani CP (2005) Optimizing chemotherapy for advanced non-small cell lung cancer: focus on docetaxel. Lung Cancer 50(Suppl 2):S3–S8PubMedCrossRefGoogle Scholar
  7. 7.
    Berkenblit A, Seiden MV, Matulonis UA, Penson RT, Krasner CN, Roche M, Mezzetti L, Atkinson T, Cannistra SA (2004) A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer. Gynecol Oncol 95:624–631PubMedCrossRefGoogle Scholar
  8. 8.
    Bruno R, Hille D, Riva A, Vivier N, ten Bokkel Huinnink WW, van Oosterom AT, Kaye SB, Verweij J, Fossella FV, Valero V, Rigas JR, Seidman AD, Chevallier B, Fumoleau P, Burris HA, Ravdin PM, Sheiner LB (1998) Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 16:187–196PubMedGoogle Scholar
  9. 9.
    Charleson HA, Bailey RR, Stewart A (1980) Quick prediction of creatinine clearance without the necessity of urine collection. N Z Med J 92:425–426PubMedGoogle Scholar
  10. 10.
    Chong BH (1995) Heparin-induced thrombocytopenia. Br J Haematol 89:431–439PubMedCrossRefGoogle Scholar
  11. 11.
    Chong BH, Eisbacher M (1998) Pathophysiology and laboratory testing of heparin-induced thrombocytopenia. Semin Hematol 35:3–8; discussion 35–36PubMedGoogle Scholar
  12. 12.
    Cohn DE, Valmadre S, Resnick KE, Eaton LA, Copeland LJ, Fowler JM (2006) Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer. Gynecol Oncol 102:134–139PubMedCrossRefGoogle Scholar
  13. 13.
    Dvorak HF (2002) Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20:4368–4380PubMedCrossRefGoogle Scholar
  14. 14.
    Eckhardt SG, Burris HA, Eckardt JR, Weiss G, Rodriguez G, Rothenberg M, Rinaldi D, Barrington R, Kuhn JG, Masuo K, Sudo K, Atsumi R, Oguma T, Higashi L, Fields S, Smetzer L, Von Hoff DD (1996) A phase I clinical and pharmacokinetic study of the angiogenesis inhibitor, tecogalan sodium. Ann Oncol 7:491–496PubMedGoogle Scholar
  15. 15.
    Edovitsky E, Elkin M, Zcharia E, Peretz T, Vlodavsky I (2004) Heparanase gene silencing, tumor invasiveness, angiogenesis, and metastasis. J Natl Cancer Inst 96:1219–1230PubMedCrossRefGoogle Scholar
  16. 16.
    El-Assal ON, Yamanoi A, Ono T, Kohno H, Nagasue N (2001) The clinicopathological significance of heparanase and basic fibroblast growth factor expressions in hepatocellular carcinoma. Clin Cancer Res 7:1299–1305PubMedGoogle Scholar
  17. 17.
    Folkman J (1995) Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 333:1757–1763PubMedCrossRefGoogle Scholar
  18. 18.
    Ganjoo K (2007) Antiangiogenesis: a new approach to the treatment of lymphoma. Leuk Lymphoma 48:454–455PubMedCrossRefGoogle Scholar
  19. 19.
    Gervais R, Ducolone A, Breton JL, Braun D, Lebeau B, Vaylet F, Debieuvre D, Pujol JL, Tredaniel J, Clouet P, Quoix E (2005) Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC). Ann Oncol 16:90–96PubMedCrossRefGoogle Scholar
  20. 20.
    Gustafson DL, Long ME, Zirrolli JA, Duncan MW, Holden SN, Pierson AS, Eckhardt SG (2003) Analysis of docetaxel pharmacokinetics in humans with the inclusion of later sampling time-points afforded by the use of a sensitive tandem LCMS assay. Cancer Chemother Pharmacol 52:159–166PubMedCrossRefGoogle Scholar
  21. 21.
    Hainsworth JD (2004) Practical aspects of weekly docetaxel administration schedules. Oncologist 9:538–545PubMedCrossRefGoogle Scholar
  22. 22.
    Hainsworth JD, Burris HA III, Yardley DA, Bradof JE, Grimaldi M, Kalman LA, Sullivan T, Baker M, Erland JB, Greco FA (2001) Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol 19:3500–3505PubMedGoogle Scholar
  23. 23.
    Hurria A, Fleming MT, Baker SD, Kelly WK, Cutchall K, Panageas K, Caravelli J, Yeung H, Kris MG, Gomez J, Miller VA, D’Andrea G, Scher HI, Norton L, Hudis C (2006) Pharmacokinetics and toxicity of weekly docetaxel in older patients. Clin Cancer Res 12:6100–6105PubMedCrossRefGoogle Scholar
  24. 24.
    Ji Y, Li Y, Nebiyou Bekele B (2007) Dose-finding in phase I clinical trials based on toxicity probability intervals. Clin Trials 4:235–244PubMedCrossRefGoogle Scholar
  25. 25.
    Koliopanos A, Friess H, Kleeff J, Shi X, Liao Q, Pecker I, Vlodavsky I, Zimmermann A, Buchler MW (2001) Heparanase expression in primary and metastatic pancreatic cancer. Cancer Res 61:4655–4659PubMedGoogle Scholar
  26. 26.
    Lilenbaum RC, Schwartz MA, Seigel L, Belette F, Blaustein A, Wittlin FN, Davila E (2001) Phase II trial of weekly docetaxel in second-line therapy for nonsmall cell lung carcinoma. Cancer 92:2158–2163PubMedCrossRefGoogle Scholar
  27. 27.
    Lynch T Jr, Kim E (2005) Optimizing chemotherapy and targeted agent combinations in NSCLC. Lung Cancer 50(S2):S25–S32PubMedCrossRefGoogle Scholar
  28. 28.
    Mey U, Gorschluter M, Ziske C, Kleinschmidt R, Glasmacher A, Schmidt-Wolf IG (2003) Weekly docetaxel in patients with pretreated metastatic breast cancer: a phase II trial. Anticancer Drugs 14:233–238PubMedCrossRefGoogle Scholar
  29. 29.
    Miao HQ, Liu H, Navarro E, Kussie P, Zhu Z (2006) Development of heparanase inhibitors for anti-cancer therapy. Curr Med Chem 13:2101–2111PubMedCrossRefGoogle Scholar
  30. 30.
    Mikami S, Ohashi K, Katsube K, Nemoto T, Nakajima M, Okada Y (2004) Coexpression of heparanase, basic fibroblast growth factor and vascular endothelial growth factor in human esophageal carcinomas. Pathol Int 54:556–563PubMedCrossRefGoogle Scholar
  31. 31.
    Mikami S, Ohashi K, Usui Y, Nemoto T, Katsube K, Yanagishita M, Nakajima M, Nakamura K, Koike M (2001) Loss of syndecan-1 and increased expression of heparanase in invasive esophageal carcinomas. Jpn J Cancer Res 92:1062–1073PubMedGoogle Scholar
  32. 32.
    Nagy JA, Vasile E, Feng D, Sundberg C, Brown LF, Detmar MJ, Lawitts JA, Benjamin L, Tan X, Manseau EJ, Dvorak AM, Dvorak HF (2002) Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. J Exp Med 196:1497–1506PubMedCrossRefGoogle Scholar
  33. 33.
    Panares RL, Garcia AA (2007) Bevacizumab in the management of solid tumors. Expert Rev Anticancer Ther 7:433–445PubMedCrossRefGoogle Scholar
  34. 34.
    Parish CR, Freeman C, Brown KJ, Francis DJ, Cowden WB (1999) Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity. Cancer Res 59:3433–3441PubMedGoogle Scholar
  35. 35.
    Pavlakis N, Parish C, Freeman C et al (2000) The heparanase inhibitor PI-88 reduces tumor growth in two rat mammary adenocarcinoma models, demonstrating schedule dependency and possible synergy with cisplatin (abstr). Proc Am Assoc Cancer ResGoogle Scholar
  36. 36.
    Progen, Industries, Ltd (2004) Investigator’s brochure on PI-88. Progen Industries Ltd, Darra, Queensland, Australia. July 2004. (unpublished) Progen Industries LtdGoogle Scholar
  37. 37.
    Ramaswamy B, Elias AD, Kelbick NT, Dodley A, Morrow M, Hauger M, Allen J, Rhoades C, Kendra K, Chen HX, Eckhardt SG, Shapiro CL (2006) Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients. Clin Cancer Res 12:3124–3129PubMedCrossRefGoogle Scholar
  38. 38.
    Ramaswamy B, Shapiro CL (2003) Phase II trial of bevacizumab in combination with docetaxel in women with advanced breast cancer. Clin Breast Cancer 4:292–294PubMedCrossRefGoogle Scholar
  39. 39.
    Ranieri G, Patruno R, Ruggieri E, Montemurro S, Valerio P, Ribatti D (2006) Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. Curr Med Chem 13:1845–1857PubMedCrossRefGoogle Scholar
  40. 40.
    Robertshaw M, Lai KN, Swaminathan R (1989) Prediction of creatinine clearance from plasma creatinine: comparison of five formulae. Br J Clin Pharmacol 28:275–280PubMedGoogle Scholar
  41. 41.
    Rosen L (2000) Antiangiogenic strategies and agents in clinical trials. Oncologist 5(Suppl 1):20–27PubMedCrossRefGoogle Scholar
  42. 42.
    Rosenthal MA, Rischin D, McArthur G, Ribbons K, Chong B, Fareed J, Toner G, Green MD, Basser RL (2002) Treatment with the novel anti-angiogenic agent PI-88 is associated with immune-mediated thrombocytopenia. Ann Oncol 13:770–776PubMedCrossRefGoogle Scholar
  43. 43.
    Schuette W, Nagel S, Blankenburg T, Lautenschlaeger C, Hans K, Schmidt EW, Dittrich I, Schweisfurth H, von Weikersthal LF, Raghavachar A, Reissig A, Serke M (2005) Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. J Clin Oncol 23:8389–8395PubMedCrossRefGoogle Scholar
  44. 44.
    Sheridan D, Carter C, Kelton JG (1986) A diagnostic test for heparin-induced thrombocytopenia. Blood 67:27–30PubMedGoogle Scholar
  45. 45.
    Shteper PJ, Zcharia E, Ashhab Y, Peretz T, Vlodavsky I, Ben-Yehuda D (2003) Role of promoter methylation in regulation of the mammalian heparanase gene. Oncogene 22:7737–7749PubMedCrossRefGoogle Scholar
  46. 46.
    Simizu S, Ishida K, Wierzba MK, Sato TA, Osada H (2003) Expression of heparanase in human tumor cell lines and human head and neck tumors. Cancer Lett 193:83–89PubMedCrossRefGoogle Scholar
  47. 47.
    Tabernero J, Climent MA, Lluch A, Albanell J, Vermorken JB, Barnadas A, Anton A, Laurent C, Mayordomo JI, Estaun N, Losa I, Guillem V, Garcia-Conde J, Tisaire JL, Baselga J (2004) A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 15:1358–1365PubMedCrossRefGoogle Scholar
  48. 48.
    Taipale J, Keski-Oja J (1997) Growth factors in the extracellular matrix. Faseb J 11:51–59PubMedGoogle Scholar
  49. 49.
    Therasse P (2002) Measuring the clinical response. What does it mean? Eur J Cancer 38:1817–1823PubMedCrossRefGoogle Scholar
  50. 50.
    Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216PubMedCrossRefGoogle Scholar
  51. 51.
    Turnbull J, Powell A, Guimond S (2001) Heparan sulfate: decoding a dynamic multifunctional cell regulator. Trends Cell Biol 11:75–82PubMedCrossRefGoogle Scholar
  52. 52.
    van Hinsbergh VW, Collen A, Koolwijk P (1999) Angiogenesis and anti-angiogenesis: perspectives for the treatment of solid tumors. Ann Oncol 10(Suppl 4):60–63PubMedCrossRefGoogle Scholar
  53. 53.
    Xu X, Rao G, Quiros RM, Kim AW, Miao HQ, Brunn GJ, Platt JL, Gattuso P, Prinz RA (2007) In vivo and in vitro degradation of heparan sulfate (HS) proteoglycans by HPR1 in pancreatic adenocarcinomas. Loss of cell surface HS suppresses fibroblast growth factor 2-mediated cell signaling and proliferation. J Biol Chem 282:2363–2373PubMedCrossRefGoogle Scholar
  54. 54.
    Yayon A, Klagsbrun M, Esko JD, Leder P, Ornitz DM (1991) Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 64:841–848PubMedCrossRefGoogle Scholar
  55. 55.
    Zhang W, Gordon M, Lenz HJ (2006) Novel approaches to treatment of advanced colorectal cancer with anti-EGFR monoclonal antibodies. Ann Med 38:545–551PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Laura Q. M. Chow
    • 1
    • 4
  • Daniel L. Gustafson
    • 1
  • Cindy L. O’Bryant
    • 1
  • Lia Gore
    • 1
  • Michele Basche
    • 1
  • Scott N. Holden
    • 1
  • Mark C. Morrow
    • 1
  • Stacy Grolnic
    • 1
  • Brian R. Creese
    • 2
  • Kaye L. Roberts
    • 2
  • Kat Davis
    • 2
  • Russell Addison
    • 3
  • S. Gail Eckhardt
    • 1
  1. 1.University of Colorado Heath Sciences CenterAuroraUSA
  2. 2.Progen Pharmaceuticals LtdToowongAustralia
  3. 3.Tetra Q Integrated Preclinical Drug DevelopmentUniversity of QueenslandBrisbaneAustralia
  4. 4.The Ottawa Hospital Cancer CenterOttawaCanada

Personalised recommendations